Paroxetine contraindications and warnings


The following provides information on contraindications to the use of paroxetine in general, pregnancy & amp; Breastfeeding and children. Please note that the contraindications may vary depending on the dosage form of a drug (eg tablet, syringe, ointment).

When should Paroxetine not be used?

The active substance should not be taken at:

  • Hypersensitivity to paroxetine
  • concomitant use of MAO inhibitor antidepressant medications. After discontinuation of a MAO-inhibitor drug or when changing paroxetine to these medicines, at least two weeks should elapse between the time the new drug is taken.
  • simultaneous use of the neuroleptics thioridazine and pimozide, which also act on the soul. Paroxetine increases their blood concentration and thus the risk of cardiac arrhythmias.

Paroxetine should only be given to

    under careful medical supervision and consideration of the benefits and risks

  • diabetes
  • Epilepsy
  • Liver and kidney damage
  • green star and its special forms such as narrow-angle glaucoma
  • heart disease
  • Blood sodium deficiency, for example due to liver cirrhosis or administration of drugs that cause sodium deficiency
  • bleeding.

What should you watch out for during pregnancy and lactation?

The use of the active substance during pregnancy and during breast-feeding should only take place if the doctor considers it absolutely necessary and if no therapy alternatives are available. Paroxetine can induce a high blood pressure of the lungs in the newborn (pulmonary hypertension).

Especially in the first trimester of pregnancy, paroxetine in the unborn baby can lead to heart failure.

In animal studies, paroxetine reduced the quality of the semen. In theory, this could affect fertility, but so far no impact on human fertility has been observed.

What should be considered in children?

Use in children and adolescents under 18 is not allowed.

Warnings and Precautions

  • Due to the increased risk of suicide, only the smallest possible number of tablets should be prescribed at the beginning of treatment and the patient should be closely monitored by the doctor and relatives.
  • If seizures occur in patients, the drug should be discontinued.
  • As with other serotonin reuptake inhibitors, discontinuing therapy should not lead to sudden discontinuation of the drug, but to taper off over a period of several weeks or months. Sudden termination of treatment can lead to withdrawal symptoms such as dizziness, tremor, anxiety, palpitations, and nausea.
  • Patients with severe renal impairment or hepatic dysfunction require lower doses.
  • Even if the drug has improved, depressives may still be suicidal.
  • In case of agitation, the dose should not be increased.
  • At the first sign of serotonin syndrome (sweating, shaking, nausea, difficulty concentrating, palpitations) the drug must be discontinued.
  • If depression turns into a mania (excitement, exaggerated happiness), the drug should be discontinued.
  • Diabetes patients need to carefully monitor their blood sugar while taking the drug.
  • Cardiac patients must first be screened for their heart condition before treatment.
  • Patients with glaucoma must be carefully ophthalmologically monitored during treatment with the drug.
  • The drug is not suitable for children and adolescents under the age of 18 years.
  • The medicine may increase the risk of bone fractures.
  • Reactivity may be impaired by ingesting the drug to the extent that driving a car and operating machinery are dangerous. This is especially true in conjunction with alcohol.

Sometimes medications release allergic reactions.
If you notice any signs of allergic reaction, tell your doctor or pharmacist immediately.